Late effects of intracoronary streptokinase on regional wall motion, @entity439 and @entity1002 in XXXX : results from the Western Washington Randomized Trial.

@entity1 @entity662 @entity583 @entity910 @entity5048 @entity2845 @entity1188 @entity439 @entity715 @entity1002
To determine whether intracoronary streptokinase improves late regional wall motion or reduces @entity1002 or @entity715 formation in @entity1 with @entity583 , two-dimensional echocardiography was performed at 8 +/- 3 weeks after @entity1188 in 83 @entity1 randomized to streptokinase (n = 45) or standard therapy (n = 38) in the Western Washington Intracoronary Streptokinase Trial. Among the @entity1 treated with streptokinase, the average time to treatment was 4.7 +/- 2.5 hours after the onset of @entity662 , and 67% had successful reperfusion. Regional wall motion was assessed in nine left ventricular segments on a scale of 1 to 4 (normal, @entity5048 , @entity2845 and @entity910 ). @entity1002 formation was interpreted as positive, equivocal or negative. All patients received anticoagulant therapy in the hospital and 52 received such therapy after hospital discharge. The mean (+/- SD) global (1.5 +/- 0.4 in both groups) and regional wall motion scores in the streptokinase-treated and control groups were not significantly different. The prevalence of @entity439 was 16% in both groups. @entity1002 was identified in only five @entity1 (positive identification in four, and equivocal in one), all in the streptokinase-treated group (p = NS). There were also no differences between streptokinase and control treatment in any of the echocardiographic variables in subgroups of @entity1 with anterior @entity1188 , @entity1188 , no prior @entity1188 or reperfusion with streptokinase. It is concluded that intracoronary streptokinase given relatively late in the course of @entity583 does not result in improved global or regional wall motion or a reduction in @entity1002 or @entity439 formation in survivors studied 2 months after @entity583 .
